Tuesday, June 23, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 672 of 1,261
  1. US 9453072

    Anti-IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  2. US 9453019

    Linked purine pterin HPPK inhibitors useful as antibacterial agents

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  3. US 9453028

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  4. US 9452175

    Pregnancy hormone combination for treatment of autoimmune diseases

    The Regents of the University of California · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  5. US 9453068

    Antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  6. US 9453239

    Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

    The Government of the United States of America, as represented by the Secretary Department of Health and Human Services, National Institutes of Health · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  7. US 9453078

    Modified antibody compositions, methods of making and using thereof

    CytomX Therapeutics, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  8. US 9453220

    RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  9. US 9453225

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  10. US 9453222

    Ligand-conjugated monomers

    Alnylam Pharmaceuticals, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  11. US 9453051

    Cyclosporin derivatives

    Lead Discovery Center GmbH · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  12. US 9452973

    Modulators of the relaxin receptor 1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  13. US 9452964

    Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

    Esperion Therapeutics, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  14. US 9452215

    Bourvadin derivatives and therapeutic uses thereof

    The Regents of the University of Colorado · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  15. US 9452182

    Collateral gene inactivation biomarkers and targets for cancer therapy

    The Board of Regents of the University of Texas System · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  16. US 9452186

    Enhanced stem cell composition

    Fate Therapeutics, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  17. US 9452163

    Abuse resistant pharmaceutical compositions

    RECRO GAINESVILLE LLC · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  18. US 9452221

    Poly(acrylate) polymers for in vivo nucleic acid delivery

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  19. US 9452161

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  20. US 9446080

    Compositions and methods

    Seres Therapeutics, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  21. US 9447417

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  22. US 9447419

    RNAi-mediated inhibition of tumor necrosis factor α-related conditions

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  23. US 9447468

    Compounds that modulate oxidative stress

    VTV THERAPEUTICS LLC · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  24. US 9447416

    Multiple exon skipping compositions for DMD

    Sarepta Therapeutics, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.